The Clinical Trials Network (CTN) was formed by SNMMI in 2008 to help facilitate the effective use of molecular imaging biomarkers in clinical trials. The CTN provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging biomarkers for use in the clinic. Benefits to the drug development industry include access to a registry of qualified imaging sites and biomarker manufacturers, a robust scanner validation program, access to standardized imaging protocols and clinical research education and training for site personnel. Sites' participation in the CTN contributes to improved imaging, not just in research but also in clinical practice. The molecular imaging community benefits as well: Increased standardization in trials leads to better data which then result in expanded utilization of molecular imaging biomarkers.